Healthcare / BiotechnologyNasdaqGM
$0.90
-0.05 (-5.78%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 25%
FCF escenarios
weak_data · normalized FCF $-35.8M · quality 72.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
27/100
D
Piotroski
3/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
20/100
SEC 0%
Sin guardar todavía.
Market Cap
$123M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-89.9%
↓Gross Margin
N/A
•Debt/Equity
0.13
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2020–2025 · 5 años de histórico normalizado
Revenue CAGR
+28.7%
FCF CAGR
—
FCF margin
-1151.4%
FCF / Net income
0.63x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $1.6M · net income $-29.7M · FCF $-18.8M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|---|
| Income Statement | |||||||
| Revenue | $1.6M | $1.6M | $1.0M | — | — | $2.7M | $462000.00 |
| Net Income | $-29.7M | $-29.7M | $-30.0M | $-34.0M | $-30.6M | $-8.3M | $-16.7M |
| EBITDA | $-37.2M | $-37.2M | $-50.5M | $-62.0M | $-61.7M | $-51.1M | — |
| EPS | — | — | -1.05 | -1.33 | -1.28 | -0.43 | — |
| Operating Margin | -2346.0% | -2346.0% | -4824.9% | — | — | -1899.1% | -3581.0% |
| Net Margin | -1817.1% | -1817.1% | -2920.0% | — | — | -306.6% | -3615.4% |
| Balance Sheet | |||||||
| Debt/Equity | 0.13 | 0.13 | 14.91 | 2.34 | 0.82 | 0.00 | -0.02 |
| Current Ratio | 3.40 | 3.40 | — | — | — | — | — |
| Cash Flow | |||||||
| Free Cash Flow | $-18.8M | $-18.8M | $-35.8M | $-52.5M | $-48.1M | $-32.8M | $-16.2M |
| Returns | |||||||
| ROE | -89.9% | -89.9% | -1506.9% | -264.0% | -83.0% | -17.6% | 14.7% |
| Valuation | |||||||
| P/B | 2.65 | 2.65 | 21.80 | 5.91 | 4.20 | — | — |
| Growth & Yield | |||||||
| Revenue Growth | 58.9% | 58.9% | — | — | — | 488.1% | — |
| EPS Growth | — | — | 21.1% | -3.9% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+60.3%
Start / end P/E
n/dx → n/dx
EPS bridge
-1.05 → n/d
Residual
+60.3%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.